Specifically, Dupixent is approved by the Food and Drug Administration (FDA) for use to manage the following inflammatory conditions in certain situations: atopic dermatitis (eczema) in adults and some children certain types of asthma in adults and some children chronic obstructive pulmonary disease (COPD) in adults chronic rhinosinusitis with nasal polyps in adults and some children eosinophilic esophagitis in adults and some children prurigo nodularis in adults bullous pemphigoid in adults chronic spontaneous urticaria in adults and some children allergic fungal rhinosinusitis in adults and some children Dupixent reduces inflammation associated with these conditions by blocking specific inflammation signals in your immune system called interleukin-4 (IL-4) and interleukin-13 (IL-13)
This alkaloid compound works synergistically with other bioactive constituents including palmatine, jatrorrhizine, and berbamine to create a comprehensive detoxification support system
COMPOSITION Ingrdients : L-carnitine tartrate, glule : hydroxypropyl mthyl cellulose, bitartrate de choline (anti-agglomrant : dioxyde de silicium [nano]), anti-agglomrants : starate de magnsium - dioxyde de silicium [nano], vitamine B6
Pharmaceutical companies are also trying to capitalize on the success of this model by rolling out their own platforms: Pfizer rolled out its DTC platform, PfizerForAll, in 2024, and Novo Nordisk launched its direct-to-patient program, NovoCare Pharmacy, in 2025
